Welcome
Support Centre
12 February 2012 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
A comparison of treosulfan and carboplatin in patients with ovarian cancer not suitable for treatment with cisplatin
Source of recordUK Trials
ISRCTNISRCTN88345833
Date ISRCTN assigned01/07/2001
Local reference number(s)G44
Public titleA comparison of treosulfan and carboplatin in patients with ovarian cancer not suitable for treatment with cisplatin
Scientific title
AcronymN/A
Disease/condition/study domainOvary
Study hypothesisNot provided at time of registration
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Not considered for cisplatin ≥75 mg/m2
2. Stages Ic-IV
3. Histologically proven epithelial ovarian cancer
4. Life expectancy .3 months
5. World Health Organisation (WHO) Performance status 0-3
6. Creatinine clearance ≥20 ml/min White Blood Cell (WBC) Count ≥3.5 x 10^9/l Platelets ≥100 x 10^9/l
Participants - exclusion criteriaNot provided at time of registration
Patient information material
Anticipated end date15/07/1998
Status of trialCompleted
Target number of participantsNot provided at time of registration
Interventions1. Carboplatin: 6 x (glomerular filtration rate (GFR)+ 25) mg intravvenous every 28 days for six cycles
2. Treosulfan: 7 g/m2 intravenous every 28 days for six cycles
Primary outcome measure(s)Not provided at time of registration
Secondary outcome measure(s)Not provided at time of registration
Sources of fundingCancer Research UK
Sponsor nameCancer Research UK
Sponsor detailsPO Box 123
Lincoln's Inn Fields
London
United Kingdom
WC2A 3PX
Sponsor telephone+44 (0)20 7317 5186
Sponsor fax+44 (0)20 7487 4302
Sponsor emailkate.law@cancer.org.uk
Sponsor websitehttp://www.cancer.org.uk
Contact nameDr - -
Contact detailsUKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
Contact telephone+44 (0) 20 7670 4723
Contact fax+44 (0) 20 7670 4818
Contact emailregister@ctu.mrc.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN88345833
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central